Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. CARL
CARL logo

CARL Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Carlsmed Inc (CARL) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
11.010
1 Day change
2.32%
52 Week Range
17.190
Analysis Updated At
2026/05/15
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

CARL is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock shows some constructive momentum, but there is no proprietary buy signal, no recent news catalyst, and no financial quarter data to confirm fundamental acceleration. With the current setup, the best direct call is to hold off and wait for a clearer entry or stronger confirmation rather than buying immediately.

Technical Analysis

The technical picture is mixed-to-positive. MACD histogram is positive and expanding, which supports short-term bullish momentum. However, RSI_6 at 75.51 is elevated, suggesting the stock is somewhat extended after the recent move, even though it is labeled neutral in the provided data. Moving averages are converging, which usually indicates the trend is not yet firmly established. Price at 10.77 is above the pivot (9.797) and near R1 (10.578), showing strength, but it is still below R2 (11.061). Overall, the chart suggests upward momentum, but not a clean low-risk entry for a beginner investor today.

Positive Catalysts

  • Truist and BTIG both maintain Buy ratings, which signals continued Wall Street confidence in the story. Truist specifically highlighted faster top-line growth and higher gross margin profile, which is supportive of the long-term investment thesis. The stock also has short-term technical momentum with a positive MACD histogram. The similar-pattern trend data suggests a possible 4.36% gain over the next month, which is mildly supportive.

Neutral/Negative Catalysts

  • There has been no news in the past week, so there is no fresh event-driven catalyst. AI Stock Picker shows no signal today, and SwingMax shows no recent signal, so Intellectia proprietary signals do not confirm an attractive entry. Analyst targets were both cut recently, from $20 to $18 and from $24 to $23, even though ratings stayed Buy. Hedge funds and insiders are neutral, and there is no recent congress trading data. The short-term pattern data also suggests a 60% chance of a slight decline over the next day and a larger decline over the next week.

Financial Performance

No usable latest-quarter financial snapshot was provided due to an error, so I cannot confirm recent quarterly revenue or earnings trends. The only fundamental commentary available from analysts indicates expectation for Q1 results to be in line with or better than worried investor sentiment around volumes, and Truist cited faster top-line growth and higher gross margin profile as positives. However, without the actual latest quarter season figures, the financial trend cannot be verified from the provided data.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent analyst sentiment is still positive overall: Truist kept a Buy rating but lowered its price target to $18 from $20 on 2026-04-15, and BTIG kept a Buy rating while lowering its target to $23 from $24 on 2026-04-13. The direction of targets is slightly down, but both firms remain constructive on the name. Wall Street pros appear to like the company’s growth and margin profile, while the cons view is that near-term volume anxiety and model updates have reduced target prices.

Wall Street analysts forecast CARL stock price to rise
5 Analyst Rating
Wall Street analysts forecast CARL stock price to rise
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 10.760
sliders
Low
18
Averages
20.5
High
24
Current: 10.760
sliders
Low
18
Averages
20.5
High
24
Truist
Buy
downgrade
$20 -> $18
AI Analysis
2026-04-15
Reason
Truist
Price Target
$20 -> $18
AI Analysis
2026-04-15
downgrade
Buy
Reason
Truist lowered the firm's price target on Carlsmed to $18 from $20 and keeps a Buy rating on the shares as part of a broader research note previewing Q1 results in MedTech. The firm expects Q1 performances to be in line or better than what feels like an anxious investor sentiment around Q1 volumes, the analyst tells investors in a research note. Given the company's faster top-line and higher gross margin profile however, the firm believes that the stock's higher multiple is justified relative to the average group, Truist added.
BTIG
Ryan Zimmerman
Buy
downgrade
$24 -> $23
2026-04-13
Reason
BTIG
Ryan Zimmerman
Price Target
$24 -> $23
2026-04-13
downgrade
Buy
Reason
BTIG analyst Ryan Zimmerman lowered the firm's price target on Carlsmed to $23 from $24 and keeps a Buy rating on the shares as part of a broader research name on Medical Technology. The firm is updating its models to reflect the CMS having announced its proposed rule for the FY27 inpatient prospective payment system which includes, among other things, preliminary commentary and decisions regarding new technology add-on payments, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for CARL
Unlock Now

People Also Watch